ABSTRACT
Introduction: We compare the differences in the diagnostic results of S-thyroid, a computer-aided diagnosis (CAD) software, based on two mutually perpendicular planes. Methods: Initially, 149 thyroid nodules confirmed by surgical pathology were enrolled in our study. CAD in our study was based on the ACR TI-RADS lexicon. t test, rank-sum test, and Chi-square test were used. The interclass correlation coefficient and Cohen's kappa were used to explore the correlation between CAD features. Receiver operating characteristic was plotted for different combinations of CAD features. Results: The patient's age, transverse diameter, longitudinal diameter, shape, margin, echogenicity, echogenic foci, composition, TI-RADS classification, and risk probability of nodules in the transverse and longitudinal planes were related to thyroid cancer (p < 0.05). The AUC (95%CI) of TI-RADS classification in the transverse plane of CAD is better than that of the longitudinal plane [0.90 (0.84-0.95) vs. 0.83 (0.77-0.90), p = 0.04]. The AUC (95%CI) of risk probability of nodules in the transverse planes shows no difference from that in the longitudinal plane statistically [0.90 (0.85-0.95) vs. 0.88 (0.82-0.94), p = 0.52]. The AUC (95% CI), specificity, sensitivity, and accuracy [TI-RADS classification (transverse plane) + TI-RADS classification (longitudinal plane) + risk (transverse plane) + risk (longitudinal plane)] are 0.93 (0.89-0.97), 86.15%, 90.48%, and 88.59%, respectively. Conclusion: The diagnosis of thyroid cancer in the CAD transverse plane was superior to that in the CAD longitudinal plane when using the TI-RADS classification, but there was no difference in the diagnosis between the two planes when using risk. However, the combination of CAD transverse and longitudinal planes had the best diagnostic ability.
ABSTRACT
Dysregulation of microRNA contributes to the high incidence and mortality of breast cancer. Here, we show that miR-625 was frequently down-regulated in breast cancer. Decrease of miR-625 was closely associated with estrogen receptor (P = 0.004), human epidermal growth factor receptor 2 (P = 0.003) and clinical stage (P = 0.001). Kaplan-Meier and multivariate analyses indicated miR-625 as an independent factor for unfavorable prognosis (hazard ratio = 2.654, 95% confident interval: 1.300-5.382, P = 0.007). Re-expression of miR-625 impeded, whereas knockdown of miR-625 enhanced cell viabilities and migration abilities in breast cancer cells. HMGA1 was confirmed as a direct target of miR-625. The expressions of HMGA1 mRNA and protein were induced by miR-625 mimics, but reduced by miR-625 inhibitor. Re-introduction of HMGA1 in cells expressing miR-625 distinctly abrogated miR-625-mediated inhibition of cell growth. Taken together, our data demonstrate that miR-625 suppresses cell proliferation and migration by targeting HMGA1 and suggest miR-625 as a promising prognostic biomarker and a potential therapeutic target for breast cancer.
